title: Current approaches in ovarian cancer vaccines.
abstract: Much of the current approaches in the treatment of advanced ovarian cancer are directed towards prolongation of duration between primary treatment and remission. Immunotherapy is regarded as one attractive option for consolidation of initial therapeutic responses. In fact, immune reactivity against ovarian carcinoma can be induced by various immunotherapeutical approaches including antibodies, peptides or dendritic cell vaccines. This review provides an overview of recent clinical trials using various concepts of immunotherapy for the treatment of ovarian cancer. Possible reasons for limited clinical success as well as further progress to improve efficacy of current immune intervention strategies, e.g. by vaccines targeting a broader range of tumor-derived antigenic structures or activating diverse host immune functions, will be discussed.
authors.affiliation: Department for Gynecology and Obstetrics, University of Marburg, Marburg, Germany. silke.reinartz@med.uni-marburg.de
authors.forename: S
authors.initials: S
authors.lastname: Reinartz
authors.forename: U
authors.initials: U
authors.lastname: Wagner
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000276:immunology; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology; D014408:Biomarkers, Tumor / Q000276:immunology; D018394:CA-125 Antigen / Q000276:immunology; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D016207:Cytokines / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy; D008213:Lymphocyte Activation; D010051:Ovarian Neoplasms / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D010455:Peptides / Q000276:immunology; D010919:Placebos; D011379:Prognosis; D016499:Radioimmunotherapy; D016032:Randomized Controlled Trials as Topic; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D019496:Cancer Vaccines; D016207:Cytokines; D007155:Immunologic Factors; D010455:Peptides; D010919:Placebos; C107428:oregovomab